Paula Schleifer
Neurology with Special Qualifications in Child Neurology · Miami, FLNPI 1104952969
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 38.9% of the total.
Across 242 payments — averaging $127.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$12K
- Sanofi$7K
- Immedica Pharma US, Inc.$6K
- Zevra Therapeutics Inc$2K
- UCB, Inc.$1K
- Neurelis, Inc.$515
- plus $3K from 25 others
Across 44 payments — averaging $8259.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$264K
- Genentech, Inc.$26K
- Ionis Pharmaceuticals, Inc.$21K
- CSL Behring$16K
- Zevra Therapeutics Inc$16K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$16K
- plus $4K from 1 others
What the payments were for
- Consulting fees$12,59041%
- Speaking & faculty fees$12,37040%
- Travel & lodging$5792%
- Food & beverage$5,16117%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 17 | $11,962 |
| Sanofi | 1 | $6,540 |
| Immedica Pharma US, Inc. | 12 | $5,781 |
| Zevra Therapeutics Inc | 1 | $1,650 |
| UCB, Inc. | 43 | $1,490 |
| Neurelis, Inc. | 33 | $515 |
| Jazz Pharmaceuticals Inc. | 20 | $467 |
| Sunovion Pharmaceuticals Inc. | 15 | $269 |
| Aquestive Therapeutics, Inc. | 13 | $262 |
| Eisai Inc. | 13 | $256 |
| Biogen | 7 | $196 |
| Zogenix Inc. | 6 | $169 |
| Sumitomo Pharma America, Inc. | 6 | $148 |
| Supernus Pharmaceuticals, Inc. | 8 | $136 |
| Livanova USA, Inc. | 6 | $124 |
| SK Life Science, Inc. | 6 | $119 |
| Ironshore Pharmaceuticals Inc. | 7 | $113 |
| Catalyst Pharmaceuticals, Inc. | 5 | $91 |
| Greenwich Biosciences, Inc. | 3 | $82 |
| Novartis | 5 | $77 |
| Azurity Pharmaceuticals, Inc. | 3 | $71 |
| Corium, LLC | 2 | $49 |
| AbbVie | 1 | $28 |
| Aprecia Pharmaceuticals, LLC | 2 | $27 |
| AstraZeneca | 1 | $24 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| Aucta Pharmaceuticals, Inc. | 1 | $22 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,759 in reported general payments places this provider in the 85th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in Miami
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ian MillerMiami$104K
- Matt LallasMiami$88K
- Marytery FajardoMiami$44K
- Roberto Lopez-AlberolaMiami$31K
- Anuj JayakarMiami$24K
- Walter BradleyMiami$19K
- Yashira Torres RamirezMiami$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.